Boston-based Verve Therapeutics presented strong findings Nov. 12 for a gene therapy candidate aimed at disabling the gene linked to low-density lipoprotein cholesterol.
Read the full post on Becker's Hospital Review - Healthcare News
Experimental gene therapy halves cholesterol in small study
